Loss of Catalytically Inactive Lipid Phosphatase Myotubularin-related Protein 12 Impairs Myotubularin Stability and Promotes Centronuclear Myopathy in Zebrafish

English version České info

X-linked myotubular myopathy (XLMTM) is a congenital disorder caused by mutations of the myotubularin gene, MTM1. Myotubularin belongs to a large family of conserved lipid phosphatases that include both catalytically active and inactive myotubularin-related proteins (i.e., “MTMRs”). Biochemically, catalytically inactive MTMRs have been shown to form heteroligomers with active members within the myotubularin family through protein-protein interactions. However, the pathophysiological significance of catalytically inactive MTMRs remains unknown in muscle. By in vitro as well as in vivo studies, we have identified that catalytically inactive myotubularin-related protein 12 (MTMR12) binds to myotubularin in skeletal muscle. Knockdown of the mtmr12 gene in zebrafish resulted in skeletal muscle defects and impaired motor function. Analysis of mtmr12 morphant fish showed pathological changes with central nucleation, disorganized Triads, myofiber hypotrophy and whorled membrane structures similar to those seen in X-linked myotubular myopathy. Biochemical studies showed that deficiency of MTMR12 results in reduced levels of myotubularin protein in zebrafish and mammalian C2C12 cells. Loss of myotubularin also resulted in reduction of MTMR12 protein in C2C12 cells, mice and humans. Moreover, XLMTM mutations within the myotubularin interaction domain disrupted binding to MTMR12 in cell culture. Analysis of human XLMTM patient myotubes showed that mutations that disrupt the interaction between myotubularin and MTMR12 proteins result in reduction of both myotubularin and MTMR12. These studies strongly support the concept that interactions between myotubularin and MTMR12 are required for the stability of their functional protein complex in normal skeletal muscles. This work highlights an important physiological function of catalytically inactive phosphatases in the pathophysiology of myotubular myopathy and suggests a novel therapeutic approach through identification of drugs that could stabilize the myotubularin-MTMR12 complex and hence ameliorate this disorder.

Vyšlo v časopise: Loss of Catalytically Inactive Lipid Phosphatase Myotubularin-related Protein 12 Impairs Myotubularin Stability and Promotes Centronuclear Myopathy in Zebrafish. PLoS Genet 9(6): e32767. doi:10.1371/journal.pgen.1003583
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003583

Souhrn

Zdroje

1. LaporteJ, HuLJ, KretzC, MandelJL, KioschisP, et al. (1996) A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 13: 175–182.

2. Buj-BelloA, BiancalanaV, MoutouC, LaporteJ, MandelJL (1999) Identification of novel mutations in the MTM1 gene causing severe and mild forms of X-linked myotubular myopathy. Hum Mutat 14: 320–325.

3. PiersonCR, TomczakK, AgrawalP, MoghadaszadehB, BeggsAH (2005) X-linked myotubular and centronuclear myopathies. J Neuropathol Exp Neurol 64: 555–564.

4. BlondeauF, LaporteJ, BodinS, Superti-FurgaG, PayrastreB, et al. (2000) Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Hum Mol Genet 9: 2223–2229.

5. TaylorGS, MaehamaT, DixonJE (2000) Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. Proc Natl Acad Sci U S A 97: 8910–8915.

6. SchaletzkyJ, DoveSK, ShortB, LorenzoO, ClagueMJ, et al. (2003) Phosphatidylinositol-5-phosphate activation and conserved substrate specificity of the myotubularin phosphatidylinositol 3-phosphatases. Curr Biol 13: 504–509.

7. CaldwellKK, LipsDL, BansalVS, MajerusPW (1991) Isolation and characterization of two 3-phosphatases that hydrolyze both phosphatidylinositol 3-phosphate and inositol 1,3-bisphosphate. The Journal of biological chemistry 266: 18378–18386.

8. Di PaoloG, De CamilliP (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443: 651–657.

9. VicinanzaM, D'AngeloG, Di CampliA, De MatteisMA (2008) Phosphoinositides as regulators of membrane trafficking in health and disease. Cellular and molecular life sciences : CMLS 65: 2833–2841.

10. Buj-BelloA, LaugelV, MessaddeqN, ZahreddineH, LaporteJ, et al. (2002) The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc Natl Acad Sci U S A 99: 15060–15065.

11. PiersonCR, Dulin-SmithAN, DurbanAN, MarshallML, MarshallJT, et al. (2011) Modeling the human MTM1 p.R69C mutation in murine Mtm1 results in exon 4 skipping and a less severe myotubular myopathy phenotype. Hum Mol Genet 21(4): 811–25.

12. BeggsAH, BohmJ, SneadE, KozlowskiM, MaurerM, et al. (2010) MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers. Proc Natl Acad Sci U S A 107: 14697–14702.

13. DowlingJJ, VreedeAP, LowSE, GibbsEM, KuwadaJY, et al. (2009) Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet 5: e1000372.

14. HniaK, VaccariI, BolinoA, LaporteJ (2012) Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology. Trends Mol Med 18(6): 317–27.

15. WishartMJ, DixonJE (2002) PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol 12: 579–585.

16. LecompteO, PochO, LaporteJ (2008) PtdIns5P regulation through evolution: roles in membrane trafficking? Trends in biochemical sciences 33: 453–460.

17. WagnerA (1996) Genetic redundancy caused by gene duplications and its evolution in networks of transcriptional regulators. Biol Cybern 74: 557–567.

18. AmoasiiL, BertazziDL, TronchereH, HniaK, ChicanneG, et al. (2012) Phosphatase-dead myotubularin ameliorates x-linked centronuclear myopathy phenotypes in mice. PLoS genetics 8: e1002965.

19. LaporteJ, BlondeauF, GansmullerA, LutzY, VoneschJL, et al. (2002) The PtdIns3P phosphatase myotubularin is a cytoplasmic protein that also localizes to Rac1-inducible plasma membrane ruffles. J Cell Sci 115: 3105–3117.

20. KimSA, VacratsisPO, FiresteinR, ClearyML, DixonJE (2003) Regulation of myotubularin-related (MTMR)2 phosphatidylinositol phosphatase by MTMR5, a catalytically inactive phosphatase. Proc Natl Acad Sci U S A 100: 4492–4497.

21. ZouJ, ChangSC, MarjanovicJ, MajerusPW (2009) MTMR9 increases MTMR6 enzyme activity, stability, and role in apoptosis. J Biol Chem 284: 2064–2071.

22. ZouJ, ZhangC, MarjanovicJ, KisselevaMV, MajerusPW, et al. (2012) Myotubularin-related protein (MTMR) 9 determines the enzymatic activity, substrate specificity, and role in autophagy of MTMR8. Proc Natl Acad Sci U S A 109: 9539–9544.

23. BolinoA, MugliaM, ConfortiFL, LeGuernE, SalihMA, et al. (2000) Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 25: 17–19.

24. AzzedineH, BolinoA, TaiebT, BiroukN, Di DucaM, et al. (2003) Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet 72: 1141–1153.

25. SenderekJ, BergmannC, WeberS, KetelsenUP, SchorleH, et al. (2003) Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 12: 349–356.

26. NgAA, LoganAM, SchmidtEJ, RobinsonFL (2013) The CMT4B disease-causing phosphatases Mtmr2 and Mtmr13 localize to the Schwann cell cytoplasm and endomembrane compartments, where they depend upon each other to achieve wild-type levels of protein expression. Human molecular genetics 22: 1493–1506.

27. BolinoA, BolisA, PrevitaliSC, DinaG, BussiniS, et al. (2004) Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. J Cell Biol 167: 711–721.

28. FiresteinR, NagyPL, DalyM, HuieP, ContiM, et al. (2002) Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase Sbf1. J Clin Invest 109: 1165–1172.

29. LorenzoO, UrbeS, ClagueMJ (2006) Systematic analysis of myotubularins: heteromeric interactions, subcellular localisation and endosome related functions. J Cell Sci 119: 2953–2959.

30. NandurkarHH, LaytonM, LaporteJ, SelanC, CorcoranL, et al. (2003) Identification of myotubularin as the lipid phosphatase catalytic subunit associated with the 3-phosphatase adapter protein, 3-PAP. Proc Natl Acad Sci U S A 100: 8660–8665.

31. OtiM, SnelB, HuynenMA, BrunnerHG (2006) Predicting disease genes using protein-protein interactions. J Med Genet 43: 691–698.

32. MicheleDE, BarresiR, KanagawaM, SaitoF, CohnRD, et al. (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418: 417–422.

33. NandurkarHH, CaldwellKK, WhisstockJC, LaytonMJ, GaudetEA, et al. (2001) Characterization of an adapter subunit to a phosphatidylinositol (3)P 3-phosphatase: identification of a myotubularin-related protein lacking catalytic activity. Proc Natl Acad Sci U S A 98: 9499–9504.

34. DowlingJJ, LowSE, BustaAS, FeldmanEL (2010) Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy. Human molecular genetics 19: 2668–2681.

35. HniaK, TronchereH, TomczakKK, AmoasiiL, SchultzP, et al. (2011) Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle. J Clin Invest 121: 70–85.

36. MochizukiY, MajerusPW (2003) Characterization of myotubularin-related protein 7 and its binding partner, myotubularin-related protein 9. Proc Natl Acad Sci U S A 100: 9768–9773.

37. RobinsonFL, NiesmanIR, BeiswengerKK, DixonJE (2008) Loss of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot-Marie-Tooth 4B2-like peripheral neuropathy in mice. Proc Natl Acad Sci U S A 105: 4916–4921.

38. ChoudhuryP, SrivastavaS, LiZ, KoK, AlbaqumiM, et al. (2006) Specificity of the myotubularin family of phosphatidylinositol-3-phosphatase is determined by the PH/GRAM domain. J Biol Chem 281: 31762–31769.

39. BergerP, BergerI, SchaffitzelC, TersarK, VolkmerB, et al. (2006) Multi-level regulation of myotubularin-related protein-2 phosphatase activity by myotubularin-related protein-13/set-binding factor-2. Hum Mol Genet 15: 569–579.

40. LievensS, CaligiuriM, KleyN, TavernierJ (2012) The use of mammalian two-hybrid technologies for high-throughput drug screening. Methods 58(4): 335–42.

41. Westerfield M (2007) The Zebrafish Book. Eugene: University of Oregon Press.

42. ThisseC, ThisseB (2008) High-resolution in situ hybridization to whole-mount zebrafish embryos. Nature protocols 3: 59–69.

43. GuptaV, KawaharaG, GundrySR, ChenAT, LencerWI, et al. (2011) The zebrafish dag1 mutant: a novel genetic model for dystroglycanopathies. Hum Mol Genet 20: 1712–1725.

44. ToschV, VasliN, KretzC, NicotAS, GasnierC, et al. (2010) Novel molecular diagnostic approaches for X-linked centronuclear (myotubular) myopathy reveal intronic mutations. Neuromuscul Disord 20: 375–381.